Novel pyridazinone derivatives with methoxy and phenyl hydrazine show strong in silico anticancer activity against ERα, suggesting potential in drug development.
Key Points
The synthesized novel pyridazinone derivatives exhibited significant anticancer potential through in silico evaluation.
Molecular docking results indicated strong binding affinities, with one compound reaching –9.1971 kcal/mol binding free energy.
The study employed multi-step synthesis, characterization techniques, and in silico docking against estrogen receptor α.
Enhancing methoxy substitution in pyridazinone may lead to improved cytotoxic activity against cancer cells.